Hormones & Longevity
Endocrine health, metabolic markers, and protocols at the frontier of longevity medicine.
From the magazine · 16
All articles →Exploring Interventions and Their Impact on Women's Hormone Health
A review of current research examines various dietary and supplemental interventions, including ashwagandha, caloric restriction, and time-restricted eating, and their observed effects on key hormones such as cortisol, testosterone, and DHEAS in women.
Exploring Interventions and Their Impact on Women's Hormone Health
A recent database compilation reviews various interventions, including supplements and dietary strategies, and their observed effects on key hormones relevant to women's health. The findings highlight both promising areas and those requiring further investigation.
Semaglutide Shows Potential to Slow Aging and Extend Lifespan in Female Mice
New research in mice suggests that semaglutide, a GLP-1 receptor agonist, may offer benefits beyond its known effects on diabetes and weight loss, potentially influencing the aging process and lifespan.
NIH Panel Identifies Research Priorities for Improving Health During Menopausal Transition
A recent workshop organized by the National Institutes of Health (NIH) has led to a draft report outlining critical research priorities to enhance health outcomes during the menopausal transition. This initiative aims to address current gaps in understanding and managing this significant life stage.
Understanding Variable Responses to GLP-1 Drugs for Weight Loss
While GLP-1 medications are highly effective for weight loss in many individuals, a significant portion experiences minimal or no benefit. Researchers are actively investigating factors such as biological sex, genetics, and behavioral elements to understand this variability and develop more personalized treatment approaches [1].
Early Menopausal Hormone Therapy May Reduce Heart Disease Risk, Study Suggests
New research indicates that initiating menopausal hormone therapy (MHT) during perimenopause or early postmenopause could significantly lower a woman's risk of cardiovascular disease. The protective effect was most pronounced when therapy began within 10 years of menopause onset.
GLP-1 Drug Shows Promise in Slowing Aging and Extending Lifespan in Mice
New research indicates that a GLP-1 drug, semaglutide, can slow the aging process and extend the lifespan of female mice, improving age-related functions. This effect appears to operate through mechanisms distinct from those of calorie restriction, offering new avenues for understanding and potentially combating age-related decline [1].
Long-Term WHI Study Finds No Overall Link Between Menopausal Hormone Therapy and Liver Cancer
A long-term follow-up of the Women's Health Initiative (WHI) randomized trials investigated the relationship between menopausal hormone therapy (MHT) and primary liver cancer incidence and mortality. The study, spanning nearly 24 years, found no overall association between MHT and liver cancer, though some subgroup findings warrant further investigation [1].
GLP-1 Drugs Show Promise in Extending Lifespan and Slowing Aging in Mice
A recent study published in Nature suggests that GLP-1 receptor agonists, commonly used for obesity and type 2 diabetes, may have anti-aging properties. The research found that older female mice treated with semaglutide lived longer and exhibited fewer signs of aging compared to control groups [1].
Trends in Menopausal Hormone Therapy Dispensing in Sweden Over 15 Years
A recent Swedish study tracked menopausal hormone therapy (MHT) dispensing patterns over 15 years, revealing a decline in systemic MHT use while local MHT increased. The research highlights how age, evolving guidelines, and socioeconomic factors influence MHT choices [1].
Are GLP-1s the First Longevity Drugs? Exploring Their Potential Beyond Metabolic Conditions
GLP-1 receptor agonists, widely known for treating obesity and type 2 diabetes, are now being considered for their potential to act as longevity drugs by addressing multiple age-related conditions. This shift reflects a growing focus on preventive medicine and targeting the mechanisms of aging itself [1].
Menopause and Hormone Use Linked to Bladder Health and Lower Urinary Tract Symptoms
A recent study indicates that women in perimenopause and postmenopause experience worse bladder health and more lower urinary tract symptoms compared to premenopausal women. Hormone use, particularly in postmenopausal women, was also associated with poorer bladder health outcomes.
The Impact of Exercise on Cognitive Function and Brain Health: A Review of Current Evidence
Regular physical activity has been consistently linked to improved cognitive function and a reduced risk of neurodegenerative diseases. This review synthesizes current research on how exercise influences brain health across different life stages.
Testosterone Therapy in Men: Who It’s For—and What It Might Cost
Testosterone therapy can be transformative for men with true hypogonadism, but its role in age-related low T is far less clear. Here’s what the evidence says about indications, benefits, and real-world risks.
Menopause hormone therapy: what the modern evidence really shows
Once vilified, menopausal hormone therapy is being reconsidered through a more nuanced, data-driven lens. Here’s what contemporary evidence says about benefits, risks, and who is most likely to gain from treatment.
GLP‑1 drugs beyond weight loss: what longevity science is really finding
GLP‑1 receptor agonists are now marketed as weight‑loss blockbusters, but emerging data suggest broader cardiometabolic, kidney, liver, and brain effects that may matter for healthy longevity—alongside real uncertainties and risks.